Semaglutide phase 3 in T1D with obesity

Danish investigator-initiated phase 3 trial testing semaglutide 2.4 mg for weight, insulin-dose needs, glycemic outcomes, hypoglycemia and DKA safety in adults with established T1D and obesity.